Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890567 | 0.79 | SLC6A4 (0.66) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL24105648 | 0.79 | SLC6A4 (0.66) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL896368 | 0.79 | SLC6A4 (0.60) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL178622 | 0.79 | SLC6A4 (0.60) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL2958349 | 0.78 | SLC6A4 (0.58) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL21089970 | 0.78 | CYP1A2 (0.61) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL10395444 | 0.78 | SLC6A4 (0.63) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8260628 | 0.78 | TAAR1 (0.52) | SLC6A4SIGMAR1CYP2D6ADRB2ADRB3 | |
| SCHEMBL16383872 | 0.78 | SLC6A4 (0.58) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL29410112 | 0.78 | SLC6A4 (0.58) | SLC6A4L3MBTL1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LTD (IN) | 2022-02-17 | — | — | US | disclosed |
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-10774059-B2 | Compositions and methods for the treatment of inflammation | CELLIX BIO PRIVATE LIMITED (IN) | 2020-09-15 | — | — | US | disclosed |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | APC, LPXN, SCNN1G | SLC6A4 399/4885L3MBTL1 4424/4885MEN1 1119/4885 |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IL1B, IL36G, IL17A | SLC6A4 398/4885L3MBTL1 3693/4885MEN1 4256/4885 |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | SLC6A4 88/4885L3MBTL1 4880/4885MEN1 3871/4885 |
| US-10774059-B2 | Compositions and methods for the treatment of inflammation | IL1B, IL36G, IL17A | SLC6A4 398/4885L3MBTL1 3693/4885MEN1 4256/4885 |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | SI, SLC10A2, ALPI | SLC6A4 65/4885L3MBTL1 4798/4885MEN1 3471/4885 |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | SLC6A4 88/4885L3MBTL1 4880/4885MEN1 3871/4885 |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | SLC6A4 399/4885L3MBTL1 4424/4885MEN1 1119/4885 |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | SLC6A4 399/4885L3MBTL1 4424/4885MEN1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.